학술논문
Intramuscular mRNA BNT162b2 vaccine against SARS-CoV-2 induces neutralizing salivary IgA
Document Type
article
Author
Miri Stolovich-Rain; Sujata Kumari; Ahuva Friedman; Saveliy Kirillov; Yakov Socol; Maria Billan; Ritesh Ranjan Pal; Kathakali Das; Peretz Golding; Esther Oiknine-Djian; Salim Sirhan; Michal Bejerano Sagie; Einav Cohen-Kfir; Naama Gold; Jamal Fahoum; Manoj Kumar; Maya Elgrably-Weiss; Bing Zhou; Miriam Ravins; Yair E. Gatt; Saurabh Bhattacharya; Orly Zelig; Reuven Wiener; Dana G. Wolf; Hila Elinav; Jacob Strahilevitz; Dan Padawer; Leah Baraz; Alexander Rouvinski
Source
Frontiers in Immunology, Vol 13 (2023)
Subject
Language
English
ISSN
1664-3224
Abstract
Intramuscularly administered vaccines stimulate robust serum neutralizing antibodies, yet they are often less competent in eliciting sustainable “sterilizing immunity” at the mucosal level. Our study uncovers a strong temporary neutralizing mucosal component of immunity, emanating from intramuscular administration of an mRNA vaccine. We show that saliva of BNT162b2 vaccinees contains temporary IgA targeting the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus-2 spike protein and demonstrate that these IgAs mediate neutralization. RBD-targeting IgAs were found to associate with the secretory component, indicating their bona fide transcytotic origin and their polymeric multivalent nature. The mechanistic understanding of the high neutralizing activity provided by mucosal IgA, acting at the first line of defense, will advance vaccination design and surveillance principles and may point to novel treatment approaches and new routes of vaccine administration and boosting.